Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

Outside China, the tirzepatide products are known as Mounjaro and Zepbound ... and glucagon and is also in phase 3. Shares in Eli Lilly rose sharply in pre-market trading today after it reported ...